Public Health Trace

Get Alerts

Data Explorer

Research historical outbreak investigations and the full recall archive, with charts, trends, and advanced filters. Looking for what's happening right now instead? See current Health Alerts.

Recall totals

All FDA and USDA recalls in Public Health Trace, June 2012 to September 2026.

37,060

Total recall recordsAll FDA and USDA recalls in Public Health Trace

9,786

Class I recallsReasonable probability of serious health consequences

24,313

Class II recallsTemporary or medically reversible health consequences

2,876

Class III recallsNot likely to cause adverse health consequences

Quick insights

A snapshot of the most notable patterns across all recorded FDA and USDA recalls.

Most recalled product100 vegetarian Fenugreek Capsules 90 count, 600mg, packaged in 150cc Amber Glass Packer with White Polypropylene Cap. 53 recalls

Most common hazardLack of Assurance of Sterility 2,072 recalls

Newest recallhttp://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/freshpoint-issues-recall-due-improperly-declared-allergen-egg-chicken-salad-wedge-sandwichesPublished September 8, 2026

Most affected stateHawaii 200 recalls mention this state

State: AS ×
Clear all

Download matching recalls as CSV

CSV exports include up to 5,000 matching rows (applying your current filters), not the full dataset if it's larger.

Filters

Timeline Classification Table

Metric

Time range

Group by

View

Recalls announced by month (Year to date)

Download CSV

Source: FDA and USDA public dataLast updated September 9, 2026 ET

Summary (Year to date)

1,527 recalls have been announced year to date.
Aug 2026 was 24% lower than the previous complete period (Jul 2026: 240).
The highest complete period was Jun 2026 (297).
Sep 2026 is incomplete and not included in the figures above.

Complete data
Incomplete

Recalls by class

Recalls by class
Class	Recalls
Class II	24,313
Class I	9,786
Class III	2,876
Not Yet Classified	2

Recalls by class
Class	Recalls
Class II	24,313
Class I	9,786
Class III	2,876
Not Yet Classified	2

FDA Recall Terminated Historical recordClass II

Gelato, Benzocaine 20% Topical Gel Anesthetic Gel, Net Wt. 1 oz. (30ml), Manufactured by Keystone Industries 480 S. Democrat Rd., Gibbstown, NJ 08027, NDC# 68400-352-30.

by Keystone Industries

Reason: CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.
Published: December 25, 2024
Distribution: Nationwide

View recall →

FDA Recall United States Terminated Historical recordClass II

Impossible Foods Inc

Product: Impossible Spicy Ground Sausage Meat from plants 14oz chub,…
Reason: product may contain pieces of metal
Published: December 25, 2024
Distribution: Nationwide

View recall →

FDA Recall United States Terminated Historical recordClass II

Impossible Foods Inc

Product: Impossible Savory Ground Sausage Meat from plants 14oz chub,…
Reason: product may contain pieces of metal
Published: December 25, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 42292-040-20

by Mylan Institutional, Inc.

Reason: Subpotent and Superpotent Drug
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets, USP, 150 mcg (0.150 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-445-20

by Mylan Institutional, Inc.

Reason: Subpotent and Superpotent Drug
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets, USP, 137 mcg (0.137 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 42292-041-20

by Mylan Institutional, Inc.

Reason: Subpotent and Superpotent Drug
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-443-20

by Mylan Institutional, Inc.

Reason: Subpotent and Superpotent Drug
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 42292-039-20

by Mylan Institutional, Inc.

Reason: Subpotent and Superpotent Drug
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-442-20

by Mylan Institutional, Inc.

Reason: Subpotent and Superpotent Drug
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Dabigatran Etexilate, 150mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-475-60

by Ascend Laboratories, LLC

Reason: CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Dabigatran Etexilate, 75 mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-474-60

by Ascend Laboratories, LLC

Reason: CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 112 mcg, packaged in a) 90-count bottles (NDC 0378-1811-77) and b) 1000-count bottles (NDC 0378-1811-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason: Superpotent Drug and Subpotent Drug: potency failures obtained
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 100 mcg, packaged in a) 90-count bottles (NDC 0378-1809-77) and b) 1000-count bottles (NDC 0378-1809-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason: Superpotent Drug and Subpotent Drug: potency failures obtained
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 88 mcg, packaged in a) 90-count bottles (NDC 0378-1807-77) and b) 1000-count bottles (NDC 0378-1807-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason: Superpotent Drug and Subpotent Drug: potency failures obtained
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 75 mcg, packaged in a) 90-count bottles (NDC 0378-1805-77) and b) 1000-count bottles (NDC 0378-1805-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason: Superpotent Drug and Subpotent Drug: potency failures obtained
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 50 mcg, packaged in a) 90-count bottles (NDC 0378-1803-77) and b) 1000-count bottles (NDC 0378-1803-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason: Superpotent Drug and Subpotent Drug: potency failures obtained
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 25 mcg, packaged in a) 90-count bottles (NDC 0378-1800-77) and b) 1000-count bottles (NDC 0378-1800-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason: Superpotent Drug and Subpotent Drug: potency failures obtained
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 200 mcg, packaged in a) 90-count bottles (NDC 0378-1819-77) and b) 1000-count bottles (NDC 0378-1819-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason: Superpotent Drug and Subpotent Drug: potency failures obtained
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 175 mcg, packaged in a) 90-count bottles (NDC 0378-1817-77) and b) 1000-count bottles (NDC 0378-1817-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason: Superpotent Drug and Subpotent Drug: potency failures obtained
Published: December 18, 2024
Distribution: Nationwide

View recall →

FDA Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 150 mcg, packaged in a) 90-count bottles (NDC 0378-1815-77) and b) 1000-count bottles (NDC 0378-1815-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason: Superpotent Drug and Subpotent Drug: potency failures obtained
Published: December 18, 2024
Distribution: Nationwide

View recall →

Data last updated: September 9, 2026 ET

Recall records are summarized from official FDA and USDA sources. Notices may be updated, reclassified, terminated, or withdrawn. Always review the linked official notice for the most current instructions. Read the full medical disclaimer.